Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Fase 2-studie for å vurdere sikkerheten og effekten av ANG003

29. oktober 2026 oppdatert av: Anagram Therapeutics, Inc.

En fase 2, multicentrisk, randomisert, aktivkontrollert studie for å vurdere sikkerheten og effekten av ANG003 ved to forskjellige dosenivåer hos pasienter med eksokrin pankreasinsuffisiens på grunn av cystisk fibrose

In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

113

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • California
      • Long Beach, California, Forente stater, 90806
        • Rekruttering
        • Long Beach Memorial Medical Center
        • Ta kontakt med:
      • Los Angeles, California, Forente stater, 90033
        • Rekruttering
        • Center for Cystic Fibrosis at Keck Medical Center of USC
        • Ta kontakt med:
    • Colorado
      • Denver, Colorado, Forente stater, 80206
        • Rekruttering
        • National Jewish Health
        • Ta kontakt med:
    • Florida
      • Gainesville, Florida, Forente stater, 32610
        • Har ikke rekruttert ennå
        • University of Florida
        • Ta kontakt med:
      • Orlando, Florida, Forente stater, 32803
        • Har ikke rekruttert ennå
        • Central Florida Pulmonary Group
        • Ta kontakt med:
    • Georgia
      • Atlanta, Georgia, Forente stater, 30324
        • Rekruttering
        • Emory-Children's Healthcare of Atlanta Cystic Fibrosis Center
        • Ta kontakt med:
    • Illinois
      • Glenview, Illinois, Forente stater, 60025
        • Rekruttering
        • The Cystic Fibrosis Institute
        • Ta kontakt med:
    • Iowa
      • Iowa City, Iowa, Forente stater, 52242
        • Har ikke rekruttert ennå
        • University of Iowa
        • Ta kontakt med:
    • Kansas
      • Kansas City, Kansas, Forente stater, 66160
        • Rekruttering
        • University of Kansas Medical Center
        • Ta kontakt med:
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40506
        • Rekruttering
        • University of Kentucky
        • Ta kontakt med:
    • Maine
      • Portland, Maine, Forente stater, 04102
        • Har ikke rekruttert ennå
        • MaineHealth Pediatric Specialty Care
        • Ta kontakt med:
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Rekruttering
        • Massachusetts General Hospital
        • Ta kontakt med:
      • Boston, Massachusetts, Forente stater, 02115
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • Rekruttering
        • University of Michigan, Michigan Medicine
        • Ta kontakt med:
      • Detroit, Michigan, Forente stater, 48201
        • Rekruttering
        • Wayne State University Harper University Hospital
        • Ta kontakt med:
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55455
        • Rekruttering
        • University of Minnesota
        • Ta kontakt med:
          • Brooke Noren, RN, BSN, CCRC
          • Telefonnummer: 612-625-7995
          • E-post: boer0039@umn.edu
    • New Jersey
      • New Brunswick, New Jersey, Forente stater, 08903
        • Rekruttering
        • Rutgers - Robert Wood Johnson Medical School
        • Ta kontakt med:
    • New York
      • Valhalla, New York, Forente stater, 10595
        • Har ikke rekruttert ennå
        • New York Medical College at Westchester Medical Center
        • Ta kontakt med:
    • Ohio
      • Akron, Ohio, Forente stater, 44308
        • Rekruttering
        • Children's Hospital Medical Center of Akron
        • Ta kontakt med:
      • Cleveland, Ohio, Forente stater, 44106
        • Rekruttering
        • Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
        • Ta kontakt med:
      • Columbus, Ohio, Forente stater, 43205
      • Toledo, Ohio, Forente stater, 43606
        • Rekruttering
        • Toledo Children's Hospital
        • Ta kontakt med:
    • Pennsylvania
      • Hershey, Pennsylvania, Forente stater, 17033
        • Rekruttering
        • Hershey Medical Center Pennsylvania State University
        • Ta kontakt med:
      • Pittsburgh, Pennsylvania, Forente stater, 15224
        • Har ikke rekruttert ennå
        • University of Pittsburgh Medical Center
        • Ta kontakt med:
    • Texas
      • Dallas, Texas, Forente stater, 75207
        • Rekruttering
        • University of Texas Southwestern / Children's Health
        • Ta kontakt med:
    • Utah
      • Salt Lake City, Utah, Forente stater, 84112
        • Rekruttering
        • Adult Cystic Fibrosis Center at the University of Utah
        • Ta kontakt med:
    • Wisconsin
      • Madison, Wisconsin, Forente stater, 53792
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Har ikke rekruttert ennå
        • Froedtert & Medical College of Wisconsin
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

12 år og eldre (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Male and female subjects aged ≥12 years from the date of informed consent in the US and aged ≥18 years in the EU

  2. Confirmed and documented diagnosis of CF

  3. Diagnosed with severe EPI as defined by a fecal elastase ≤50 μg/g stool measured at Screening by a central laboratory.

  4. Subject has controlled EPI and taking a stable dose of pancreatic enzyme replacement therapy (PERT) for 90 days prior to Screening.

  5. Adequate nutritional status measured by body mass index (BMI) defined by:

    1. BMI ≥25th percentile for children aged 12-17 years
    2. BMI ≥18.5 kg/m2 for ≥18 years of age

Exclusion Criteria:

  1. History of fibrosing colonopathy or recurring distal intestinal obstructive syndrome within 6 months of Screening.
  2. History of lung or liver transplant, listing for organ transplant or significant bowel resection within the last 6 months. Subjects with a history of resection that does not result in short bowel syndrome are eligible.
  3. Known hypersensitivity or other severe reaction to any ingredient of the investigational product (IP), Creon, or the stool marker (FD&C Blue #2).
  4. Any chronic diarrheal illness unrelated to pancreatic insufficiency, actively being treated for small intestinal bacterial overgrowth, requiring use of naso-gastric, J-tube, G-tube, and/or enteral feeding for the study duration, Clostridioides difficile infection within 6 months prior to Screening, or severe constipation defined as <1 bowel movement/week.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: ANG003 Dose A

All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to ANG003 Dose A for a 21-day acclimation and subsequent CFA analysis.

160,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP])

Eksperimentell: ANG003 Dose B

All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to ANG003 Dose B for a 21-day acclimation and subsequent CFA analysis.

240,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP])

Aktiv komparator: Creon

All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to Creon for an additional 21-days and subsequent CFA analysis.

The commercially available pPERT Creon will be the active comparator in the study. Subjects will be instructed to take Creon according to the package insert and PI direction.

Ingen inngripen: Off Enzyme

All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. If baseline CFA is >/= 80%, the subject may be randomized to the off enzyme arm. Subjects will receive Creon for an additional 21-day and the subsequent CFA analysis will be off enzyme. Total time off enzyme will be 4-7 days.

Annen: 60% to <80% CFA ANG003 Dose B

All subjects will be acclimated to Creon for 14-days and then will undergo a baseline CFA analysis. Participants with a Period A CFA result of 60% to <80% will be assigned to ANG003 Dose B.

240,000 u* lipase, 105,000 u* protease, and 11,600 u* amylase per dose (*units are comparable to United States Pharmacopeiea [USP])

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory values
Tidsramme: From Visit 1 to Visit 5, anticipated average 80 days

Adverse events (AEs); Treatment-emergent AEs; Serious AEs; Discontinuation due to AEs; Clinical laboratory values

From Visit 1 to Visit 5, anticipated average 80 days
Coefficient of Fat Absorption (CFA)
Tidsramme: Period A (baseline) and Period B 72 hour CFA collection

Mean change from baseline CFA (i.e., Period B CFA minus Period A CFA) assessed for ANG003 Dose A, ANG003 Dose B, and Creon amongst subjects with baseline CFA ≥80%.

Period A (baseline) and Period B 72 hour CFA collection

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Plasma docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) (ug/mL)
Tidsramme: Period A (baseline) and Period B time 0, 1, 2, 4, 6, 8, 10 and 24 hour collections

Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%.

Period A (baseline) and Period B time 0, 1, 2, 4, 6, 8, 10 and 24 hour collections
Coefficient of Nitrogen Absorption (CNA)
Tidsramme: Period A (baseline) and Period B 72 hour CNA collection

Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%.

Period A (baseline) and Period B 72 hour CNA collection
% of subjects with GI symptoms
Tidsramme: From Visit 2 to Visit 5, anticipated average 59 days

Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%.

From Visit 2 to Visit 5, anticipated average 59 days
Cumulative stool weight
Tidsramme: Period A (baseline) and Period B 72 hour collection

Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%.

Period A (baseline) and Period B 72 hour collection
Number of Stools per Day
Tidsramme: Period A (baseline) and Period B 72 hour collection

Mean change from baseline for each treatment group amongst subjects with baseline CFA ≥80%.

Period A (baseline) and Period B 72 hour collection

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Correlation between DHA/EPA and CFA
Tidsramme: Period A (baseline) Period B 72 hour CFA and 24 hour DHA/EPA collection

Mean change from baseline for each treatment group with a baseline CFA ≥80%

Period A (baseline) Period B 72 hour CFA and 24 hour DHA/EPA collection
Coefficient of Fat Absorption (CFA) for subjects with a baseline CFA of 60% to <80% (analyzed separately)
Tidsramme: Period A (baseline) and Period B 72 hour CFA collection

Mean change from baseline for each treatment group with a baseline CFA 60% to <80%

Period A (baseline) and Period B 72 hour CFA collection
Mean Period B CFA for all subjects randomized to the Off Enzyme arm with a baseline CFA ≥80%
Tidsramme: Period B 72 hour CFA collection

Period B CFA Off Enzyme in subjects with a baseline CFA ≥80%

Period B 72 hour CFA collection

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

24. april 2026

Primær fullføring (Antatt)

1. juli 2027

Studiet fullført (Antatt)

1. juli 2027

Datoer for studieregistrering

Først innsendt

9. februar 2026

Først innsendt som oppfylte QC-kriteriene

26. februar 2026

Først lagt ut (Faktiske)

4. mars 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere